Phase 1 Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Healthy participants (Part A):
- People who are in good general health, confirmed through a medical check-up including health history, physical examination, blood tests, and a heart screening
People with Type 2 diabetes (Part A):
- People who were diagnosed with Type 2 diabetes more than 1 year before joining the trial
- People (in one specific group called Cohort 5) who have been taking a long-acting insulin — such as insulin glargine, insulin detemir, or insulin degludec — at more than 10 units per day for at least 6 months
- People whose HbA1c (a measure of average blood sugar over several months) is between 6.5% and 9.5% at the initial screening visit
People with Type 1 diabetes (Parts B and C):
- People who have had Type 1 diabetes for at least 1 year, and whose body produces very little or no insulin of its own (confirmed by a specific blood test called C-peptide)
- People whose HbA1c is between 6% and 8.5% at the initial screening visit
All participants:
- People whose blood pressure is below 140/90 mmHg (or below 150/90 mmHg for people with diabetes), and whose resting pulse rate is below 90 beats per minute
- People with Type 1 or Type 2 diabetes who are aware of when their blood sugar is dropping too low (no history of hypoglycemia unawareness)
Who may not be able to join:
- People who have visited an emergency room or been hospitalised more than once due to poorly controlled blood sugar (including very high blood sugar or a condition called diabetic ketoacidosis) in the 6 months before screening
- People who have had a severe low blood sugar episode requiring help from another person, or who have had hypoglycemia unawareness (not feeling the warning signs of low blood sugar), in the 6 months before screening
- People with a significant history of heart or cardiovascular disease
- People who have a condition called gastroparesis (where the stomach empties too slowly) or who have had surgery on their stomach
- People who have active or long-term liver inflammation (hepatitis)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Phone: 1-317-615-4559
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with One or More Serious Adverse Event(s) (SAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.